Inborn Errors of Metabolism, Metabolic Disease, Phenylketonurias, PKU
Conditions
Brief summary
The aim of this study is to demonstrate that a new protein substitute is acceptable and well tolerated in children with PKU.
Interventions
Amino acid based protein substitute
Sponsors
Study design
Eligibility
Inclusion criteria
* Diagnosis of PKU or PKU variant requiring a phenylalanine-free protein substitute * Subjects who are already taking a phenylalanine-free protein substitute and are willing to try the study product for 7 days * Patients aged 3 years of age to adulthood * Written informed consent obtained from parental caregiver
Exclusion criteria
* Presence of serious concurrent illness * Investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements * Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study. * Any patients having taken antibiotics over the previous 2 weeks leading up to the study. * Patients less than 3 years of age.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Gastrointestinal tolerance | 7 days | Questionnaire detailing any GI symptoms, severity and change from usual • The collection of daily data about the gastro-intestinal tolerance of the protein substitute. |
| Product compliance | 7 days | Daily questionnaire on amounts offered and amounts actually consumed, compared to recommended amount. |
| Product palatability | 7 days | Questionnaire data captured to evaluate taste |
| Product acceptability | 7 days | Brief tick-box questionnaire on overall liking and acceptability of product |
Countries
United Kingdom